X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare IPCA Labs with Sun Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

IPCA LABS vs SUN PHARMA - Comparison Results

IPCA LABS    Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

SUN PHARMA 
   Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    IPCA LABS SUN PHARMA IPCA LABS/
SUN PHARMA
 
P/E (TTM) x 31.0 27.6 112.1% View Chart
P/BV x 4.6 2.9 157.0% View Chart
Dividend Yield % 0.1 0.4 23.7%  

Financials

 IPCA LABS   SUN PHARMA
EQUITY SHARE DATA
    IPCA LABS
Mar-18
SUN PHARMA
Mar-18
IPCA LABS/
SUN PHARMA
5-Yr Chart
Click to enlarge
High Rs695701 99.3%   
Low Rs400433 92.3%   
Sales per share (Unadj.) Rs260.2110.4 235.7%  
Earnings per share (Unadj.) Rs19.011.0 172.8%  
Cash flow per share (Unadj.) Rs33.117.2 191.9%  
Dividends per share (Unadj.) Rs1.002.00 50.0%  
Dividend yield (eoy) %0.20.4 51.7%  
Book value per share (Unadj.) Rs213.0158.8 134.2%  
Shares outstanding (eoy) m126.202,399.26 5.3%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.15.1 41.0%   
Avg P/E ratio x28.951.6 55.9%  
P/CF ratio (eoy) x16.632.9 50.4%  
Price / Book Value ratio x2.63.6 72.0%  
Dividend payout %5.318.2 28.9%   
Avg Mkt Cap Rs m69,1201,360,021 5.1%   
No. of employees `00013.317.8 74.5%   
Total wages/salary Rs m7,35953,671 13.7%   
Avg. sales/employee Rs Th2,477.414,890.9 16.6%   
Avg. wages/employee Rs Th555.23,017.1 18.4%   
Avg. net profit/employee Rs Th180.61,480.6 12.2%   
INCOME DATA
Net Sales Rs m32,836264,895 12.4%  
Other income Rs m4188,388 5.0%   
Total revenues Rs m33,254273,282 12.2%   
Gross profit Rs m4,50556,081 8.0%  
Depreciation Rs m1,77714,998 11.8%   
Interest Rs m2405,176 4.6%   
Profit before tax Rs m2,90544,295 6.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-9,505 0.0%   
Tax Rs m5118,452 6.0%   
Profit after tax Rs m2,39426,338 9.1%  
Gross profit margin %13.721.2 64.8%  
Effective tax rate %17.619.1 92.2%   
Net profit margin %7.39.9 73.3%  
BALANCE SHEET DATA
Current assets Rs m19,455316,359 6.1%   
Current liabilities Rs m10,076198,643 5.1%   
Net working cap to sales %28.644.4 64.3%  
Current ratio x1.91.6 121.2%  
Inventory Days Days9895 103.2%  
Debtors Days Days67108 62.2%  
Net fixed assets Rs m20,260213,178 9.5%   
Share capital Rs m2522,399 10.5%   
"Free" reserves Rs m26,633378,606 7.0%   
Net worth Rs m26,886381,006 7.1%   
Long term debt Rs m2,34017,721 13.2%   
Total assets Rs m41,173643,028 6.4%  
Interest coverage x13.19.6 137.0%   
Debt to equity ratio x0.10 187.1%  
Sales to assets ratio x0.80.4 193.6%   
Return on assets %6.44.9 130.6%  
Return on equity %8.96.9 128.8%  
Return on capital %10.810.0 107.4%  
Exports to sales %47.60-   
Imports to sales %14.90-   
Exports (fob) Rs m15,642NA-   
Imports (cif) Rs m4,884NA-   
Fx inflow Rs m15,64240,816 38.3%   
Fx outflow Rs m4,88430,143 16.2%   
Net fx Rs m10,75910,673 100.8%   
CASH FLOW
From Operations Rs m3,41139,072 8.7%  
From Investments Rs m-1,354-33,708 4.0%  
From Financial Activity Rs m-1,304-15,393 8.5%  
Net Cashflow Rs m753-7,359 -10.2%  

Share Holding

Indian Promoters % 45.9 63.7 72.1%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 11.4 5.1 222.2%  
FIIs % 25.3 23.0 110.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.4 8.3 209.6%  
Shareholders   36,892 133,026 27.7%  
Pledged promoter(s) holding % 2.1 0.5 403.8%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare IPCA LABS With:   SANOFI INDIA  ABBOTT INDIA  PLETHICO PHARMA  WYETH LTD  TORRENT PHARMA  

Compare IPCA LABS With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 324 Points Lower; Metal and Telecom Stocks Witness Selling(Closing)

India share markets witnessed selling pressure during closing hours and ended their trading session on a negative note.

Related Views on News

IPCA LABS Announces Quarterly Results (3QFY19); Net Profit Up 51.7% (Quarterly Result Update)

Feb 14, 2019 | Updated on Feb 14, 2019

For the quarter ended December 2018, IPCA LABS has posted a net profit of Rs 2 bn (up 51.7% YoY). Sales on the other hand came in at Rs 9 bn (up 10.3% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

SUN PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 265.5% (Quarterly Result Update)

Feb 13, 2019 | Updated on Feb 13, 2019

For the quarter ended December 2018, SUN PHARMA has posted a net profit of Rs 15 bn (up 265.5% YoY). Sales on the other hand came in at Rs 77 bn (up 16.3% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

SUN PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Dec 20, 2018 | Updated on Dec 20, 2018

Here's an analysis of the annual report of SUN PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of SUN PHARMA. Also includes updates on the valuation of SUN PHARMA.

IPCA LABS Announces Quarterly Results (2QFY19); Net Profit Up 24.1% (Quarterly Result Update)

Nov 15, 2018 | Updated on Nov 15, 2018

For the quarter ended September 2018, IPCA LABS has posted a net profit of Rs 1 bn (up 24.1% YoY). Sales on the other hand came in at Rs 10 bn (up 15.4% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

SUN PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 110.7% (Quarterly Result Update)

Nov 14, 2018 | Updated on Nov 14, 2018

For the quarter ended September 2018, SUN PHARMA has posted a net profit of Rs 1 bn (down 110.7% YoY). Sales on the other hand came in at Rs 69 bn (up 4.3% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

More Views on News

Most Popular

This is Why the Stock of Jubilant FoodWorks Went Up 1,160%(The 5 Minute Wrapup)

Apr 12, 2019

This critical business strategy has enabled companies to scale their operations faster.

Pocketing Massive Gains with HDFC And HDFC Bank(Profit Hunter)

Apr 12, 2019

Here's how one could have generated gains of Rs 59,250 in 10 days by trading HDFC and HDFC Bank with a capital of Rs 4 lakh.

My Master Series on How to Trade Election 2019(Profit Hunter)

Apr 16, 2019

For 30 years he has watched how elections impact the markets, and practiced how to profit from it. Now he is here...telling you everything. Read on...

Election Series: Follow the World's Biggest Traders To See Where the Money Flows(The 5 Minute Wrapup)

Apr 17, 2019

20% of all the traders bring in 80% of the money. Watch these 20% and you get a working idea of which way the wind is blowing.

A Letter to You from India's No. 1 Trader(The 5 Minute Wrapup)

Apr 15, 2019

It's our great pleasure to introduce Vijay Bhambwani to our readers - we consider Vijay to be India's best trader. Read on to find out why...

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

IPCA LABS SHARE PRICE


Apr 25, 2019 (Close)

TRACK IPCA LABS

  • Track your investment in IPCA LABS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

IPCA LABS 8-QTR ANALYSIS

COMPARE IPCA LABS WITH

MARKET STATS